Study on the virulome and resistome of a vancomycin intermediate-resistance Staphylococcus aureus

Jie Fu1, Kan Wang2, Congxiu Ye3

  • 1Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China.

Microbial Pathogenesis
|April 11, 2020
PubMed

Insights

This study details the genomic features of a vancomycin-intermediate resistant Staphylococcus aureus (MRSA) strain, Guangzhou-SauVS2. It highlights the strain

Area of Science:

  • Microbiology
  • Genomics
  • Infectious Diseases

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) is a significant public health concern, often termed a "Super Bug".
  • Vancomycin is a critical antibiotic for treating MRSA infections.
  • Intermediate resistance to vancomycin in MRSA poses a growing therapeutic challenge.

Purpose of the Study:

  • To investigate the genomic characteristics of a vancomycin-intermediate resistant MRSA strain, Guangzhou-SauVS2.
  • To identify antimicrobial resistance and virulence determinants in this specific MRSA strain.
  • To understand the genetic basis of MRSA pathogenesis in a clinical context.

Main Methods:

  • Whole-genome sequencing of the S. aureus strain Guangzhou-SauVS2.
  • Bioinformatic analysis including gene annotation (GO, COG, KEGG).
  • Identification and characterization of antimicrobial resistance genes and virulence factors.

Main Results:

  • The Guangzhou-SauVS2 genome is 2,605,384 bp with 33.21% G+C content and 2,239 predicted genes.
  • The strain possesses a vancomycin B-type resistance protein conferring intermediate resistance.
  • Acquired resistance genes for beta-lactams, quinolones, macrolides, and tetracyclines were identified, alongside virulence factors (adherence, antiphagocytosis, iron uptake, toxins).

Conclusions:

  • The genomic analysis of MRSA strain Guangzhou-SauVS2 reveals a complex resistance profile beyond vancomycin.
  • The identified virulence factors contribute to the strain's pathogenic potential.
  • Understanding these genomic features is crucial for developing effective treatment strategies against multidrug-resistant MRSA.